Varun Bafna, MD, of the University of California, San Francisco, provides results from a phase 3 trial of ofirnoflast in ESA-refractory, lower-risk MDS.
Ofirnoflast, a first-in-class, oral, allosteric inhibitor of NEK7, was evaluated in 37 patients and demonstrated clinically meaningful results, according to the investigators, who shared their results at the 2026 EHA Hybrid Congress.
Leave feedback about this